Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Colorectal Neoplasms 476Carcinoma, Non-Small-Cell Lung 233Breast Neoplasms 196Ovarian Neoplasms 171Glioblastoma 157Carcinoma, Hepatocellular 131Neoplasms 128Rectal Neoplasms 114Colonic Neoplasms 110Neoplasm Metastasis 106Brain Neoplasms 97Lung Neoplasms 96Fallopian Tube Neoplasms 85Carcinoma, Renal Cell 77Glioma 69Pancreatic Neoplasms 54Liver Neoplasms 44Melanoma 43Gliosarcoma 43Uterine Cervical Neoplasms 40Adenocarcinoma of Lung 39Stomach Neoplasms 37Recurrence 33Astrocytoma 30Carcinoma, Ovarian Epithelial 28Endometrial Neoplasms 27Triple Negative Breast Neoplasms 26Kidney Neoplasms 23Prostatic Neoplasms 22Esophageal Neoplasms 21

Interventions

relacorilant 5Nutrition Assessment 4Hydrochlorothiazide 4Bevacizumab 3Amlodipine 3aliskiren 2Osilodrostat 2Lisinopril 2Labetalol 2Angiotensin-Converting Enzyme Inhibitors 2Adrenalectomy 2ziprasidone 1sacubitril and valsartan sodium hydrate drug combination 1pembrolizumab 1pazopanib 1lutetium Lu 177 dotatate 1ganirelix 1gallium Ga 68 dotatate 1fimasartan 1enzalutamide 1clevidipine 1cediranib 1bicalutamide 1benazepril 1Zolpidem 1Warfarin 1Vitamin D 1Vecuronium Bromide 1Vancomycin 1Urine Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Hypertension × Bevacizumab × Clear all
NCT00674011 2014-05-06

Hypertension in Breast Cancer Patients Receiving Bevacizumab

Dana-Farber Cancer Institute

Terminated
10 enrolled
Breast

Breast Neoplasms, Hypertension

NCT01125943 2013-01-10

Bevacizumab and Endothelium Dependent Vasodilation

Radboud University Medical Center

Phase NA Completed
24 enrolled

Hypertension, Neoplasms

NCT00929058 2010-05-18

BVZ1

Radboud University Medical Center

Phase NA Completed
10 enrolled

Hypertension, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡